Picking the wrong stocks can decimate your portfolio.
They’re pure portfolio poison.
But the right stocks…
If you pick the right stocks, you could find yourself jumping for joy on top of an enormous pile of cash.
With over 4000 tickers to choose from, finding the right stock at the right time can prove to be nearly impossible…
Unless you’re spending hours each day combing the markets and researching companies.
That’s why we’ve done the legwork for you.
We sort through thousands of stock ideas and whittle them down to a few top choices that are primed for solid price action in the coming days, weeks and months.
This week, we’ve narrowed it down to three stocks that could be getting significant attention in the near future.
Curaleaf Holdings (CURLF)
If marijuana receives reclassification as Schedule III, it could usher in a new era for medical cannabis, aligning it with pharmaceutical regulations. This transformation would be particularly advantageous for companies like Green Thumb and Curaleaf, both of which operate in this space.
Curaleaf, boasting a market cap of $4.8 billion, has experienced a remarkable 64% surge since late August. Much like Green Thumb, Curaleaf operates as a multi-state operator, with a presence in 20 states. The company manages 22 cultivation sites and 152 retail outlets, positioning itself for international expansion through strategic acquisitions. For instance, in the fourth quarter of 2022, Curaleaf secured a 55% equity stake in Four 20 Pharma, a leading medical cannabis company in Germany. With annual sales in Europe estimated at US$248 billion, Curaleaf is well-positioned to drive sales growth over the next decade, especially given its 2022 revenue of $1.77 billion. If rescheduling moves forward, Curaleaf could see its stock sustainably surpass the $5 mark, firmly establishing itself among the top cannabis stocks.
The GEO Group, Inc. (GEO)
The global government secure facilities specialist owns significant prison real estate and an extremely valuable tech platform called BI, which monitors prisoners and illegal migrants.
BI provides a GPS technology intended to enhance compliance. The electronic monitoring program tracks immigrants and prisoners via cell phones and other electronic devices. GEO has an exclusive five-year contract with ICE that ends in 2026 but will likely be renewed post-2026. This allows the company to capture 100% of the ICE market for immigrants who are under this system.
The GEO Group’s owned real estate is estimated to be worth multiples of the current enterprise value in private market transactions and BI could be worth the entire enterprise value in a spin-off or sale of the segment.
The margins are also impressive with 55% EBITDA margins and the company putting up over $270M of EBITDA in 2022 alone from the BI segment. With a share price of $7.22, GEO has a market cap of $903 million and an enterprise value of only $2.7 billion.
Citron Research thinks GEO is cheap, and the pros on Wall Street agree. The analysts covering the stock give a median 12-month target of $15, representing a 102% increase from the current price.
Taiwan Semiconductor (TSM)
Trading at a significant 37% discount from its peak in January 2022, Taiwan Semiconductor has faced challenges stemming from a decline in smartphone demand and other factors impacting PC sales. Additionally, geopolitical tensions have added an air of uncertainty. Despite concerns raised, many analysts remain optimistic, labeling TSM as a strong buy. With an average price target of $125, there’s potential for an impressive 36% upside.
Tiny Biotech Wins $75 Billion Patent
Cambridge firm proves its possible to “Find & Replace” cancer cells. The Wall Street Journal reports this small biotech is “Transforming Medicine.” No wonder Goldman Sachs & Morgan Stanley have been quietly buying shares. [Get the name of this little-known stock here >>>.]